123 related articles for article (PubMed ID: 38549430)
21. Repurposing of Zika virus live-attenuated vaccine (ZIKV-LAV) strains as oncolytic viruses targeting human glioblastoma multiforme cells.
Victorio CBL; Novera W; Ganasarajah A; Ong J; Thomas M; Wu J; Toh HSY; Sun AX; Ooi EE; Chacko AM
J Transl Med; 2024 Feb; 22(1):126. PubMed ID: 38308299
[TBL] [Abstract][Full Text] [Related]
22. Growth properties and vaccine efficacy of recombinant pseudorabies virus defective in glycoprotein E and thymidine kinase genes.
Wu CY; Liao CM; Chi JN; Chien MS; Huang C
J Biotechnol; 2016 Jul; 229():58-64. PubMed ID: 27164258
[TBL] [Abstract][Full Text] [Related]
23. Synergistic anti-tumor efficacy of oncolytic influenza viruses and B7-H3 immune- checkpoint inhibitors against IC-resistant lung cancers.
Masemann D; Meissner R; Schied T; Lichty BD; Rapp UR; Wixler V; Ludwig S
Oncoimmunology; 2021 Feb; 10(1):1885778. PubMed ID: 33643696
[TBL] [Abstract][Full Text] [Related]
24. Oncolytic virus driven T-cell-based combination immunotherapy platform for colorectal cancer.
Crupi MJF; Taha Z; Janssen TJA; Petryk J; Boulton S; Alluqmani N; Jirovec A; Kassas O; Khan ST; Vallati S; Lee E; Huang BZ; Huh M; Pikor L; He X; Marius R; Austin B; Duong J; Pelin A; Neault S; Azad T; Breitbach CJ; Stojdl DF; Burgess MF; McComb S; Auer R; Diallo JS; Ilkow CS; Bell JC
Front Immunol; 2022; 13():1029269. PubMed ID: 36405739
[TBL] [Abstract][Full Text] [Related]
25. Combination of novel oncolytic herpesvirus with paclitaxel as an efficient strategy for breast cancer therapy.
Deng X; Shen Y; Yi M; Zhang C; Zhao B; Zhong G; WeiyangLou ; Xue D; Leng Q; Ding J; Zhao R; Jia W; Dong C; Dai Z
J Med Virol; 2023 May; 95(5):e28768. PubMed ID: 37212336
[TBL] [Abstract][Full Text] [Related]
26. Fusogenic oncolytic vaccinia virus enhances systemic antitumor immune response by modulating the tumor microenvironment.
Nakatake M; Kuwano N; Kaitsurumaru E; Kurosaki H; Nakamura T
Mol Ther; 2021 May; 29(5):1782-1793. PubMed ID: 33348052
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of immunogenicity of gene-deleted and subunit vaccines constructed against the emerging pseudorabies virus variants.
Zhang HL; Zhang RH; Liu G; Li GM; Wang FX; Wen YJ; Shan H
Virol J; 2023 May; 20(1):98. PubMed ID: 37221518
[TBL] [Abstract][Full Text] [Related]
28. CD40L-armed oncolytic herpes simplex virus suppresses pancreatic ductal adenocarcinoma by facilitating the tumor microenvironment favorable to cytotoxic T cell response in the syngeneic mouse model.
Wang R; Chen J; Wang W; Zhao Z; Wang H; Liu S; Li F; Wan Y; Yin J; Wang R; Li Y; Zhang C; Zhang H; Cao Y
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35086948
[TBL] [Abstract][Full Text] [Related]
29. Intratumoral expression of interleukin 23 variants using oncolytic vaccinia virus elicit potent antitumor effects on multiple tumor models via tumor microenvironment modulation.
Chen L; Chen H; Ye J; Ge Y; Wang H; Dai E; Ren J; Liu W; Ma C; Ju S; Guo ZS; Liu Z; Bartlett DL
Theranostics; 2021; 11(14):6668-6681. PubMed ID: 34093846
[No Abstract] [Full Text] [Related]
30. A high-temperature passaging attenuated Pseudorabies vaccine protects piglets completely against emerging PRV variant.
Liang C; Tong W; Zheng H; Liu F; Wu J; Li G; Zhou EM; Tong G
Res Vet Sci; 2017 Jun; 112():109-115. PubMed ID: 28214681
[TBL] [Abstract][Full Text] [Related]
31. Oncolytic virus M1 functions as a bifunctional checkpoint inhibitor to enhance the antitumor activity of DC vaccine.
Dan J; Cai J; Zhong Y; Wang C; Huang S; Zeng Y; Fan Z; Xu C; Hu L; Zhang J; Hu J; Liu Y; Su X; Zhu W; Yan G; Liang J; Lin Y
Cell Rep Med; 2023 Oct; 4(10):101229. PubMed ID: 37820722
[TBL] [Abstract][Full Text] [Related]
32. Oncolytic herpesvirus expressing PD-L1 BiTE for cancer therapy: exploiting tumor immune suppression as an opportunity for targeted immunotherapy.
Khalique H; Baugh R; Dyer A; Scott EM; Frost S; Larkin S; Lei-Rossmann J; Seymour LW
J Immunother Cancer; 2021 Mar; 9(4):. PubMed ID: 33820820
[TBL] [Abstract][Full Text] [Related]
33. Immune Modulation by Telomerase-Specific Oncolytic Adenovirus Synergistically Enhances Antitumor Efficacy with Anti-PD1 Antibody.
Kanaya N; Kuroda S; Kakiuchi Y; Kumon K; Tsumura T; Hashimoto M; Morihiro T; Kubota T; Aoyama K; Kikuchi S; Nishizaki M; Kagawa S; Tazawa H; Mizuguchi H; Urata Y; Fujiwara T
Mol Ther; 2020 Mar; 28(3):794-804. PubMed ID: 31991110
[TBL] [Abstract][Full Text] [Related]
34. Efficacy evaluation of two live virus vaccines against an emerging pseudorabies virus variant.
Wang M; Wang L; Zhao Q
Pol J Vet Sci; 2019 Dec; 22(4):639-645. PubMed ID: 31867931
[TBL] [Abstract][Full Text] [Related]
35. An approach to a FMD vaccine based on genetic engineered attenuated pseudorabies virus: one experiment using VP1 gene alone generates an antibody responds on FMD and pseudorabies in swine.
Qian P; Li XM; Jin ML; Peng GQ; Chen HC
Vaccine; 2004 Jun; 22(17-18):2129-36. PubMed ID: 15149769
[TBL] [Abstract][Full Text] [Related]
36. Characterization of a quadruple glycoprotein-deleted pseudorabies virus mutant for use as a biologically safe live virus vaccine.
Mettenleiter TC; Klupp BG; Weiland F; Visser N
J Gen Virol; 1994 Jul; 75 ( Pt 7)():1723-33. PubMed ID: 8021601
[TBL] [Abstract][Full Text] [Related]
37. Characterization of a recombinant pseudorabies virus expressing porcine parvovirus VP2 protein and porcine IL-6.
Zheng HH; Wang LQ; Fu PF; Zheng LL; Chen HY; Liu F
Virol J; 2020 Feb; 17(1):19. PubMed ID: 32014014
[TBL] [Abstract][Full Text] [Related]
38. Exploiting Preexisting Immunity to Enhance Oncolytic Cancer Immunotherapy.
Tähtinen S; Feola S; Capasso C; Laustio N; Groeneveldt C; Ylösmäki EO; Ylösmäki L; Martins B; Fusciello M; Medeot M; Tagliamonte M; Chiaro J; Hamdan F; Peltonen K; Ranki T; Buonaguro L; Cerullo V
Cancer Res; 2020 Jun; 80(12):2575-2585. PubMed ID: 32107211
[TBL] [Abstract][Full Text] [Related]
39. Oncolytic virotherapy enhances the efficacy of a cancer vaccine by modulating the tumor microenvironment.
Koske I; Rössler A; Pipperger L; Petersson M; Barnstorf I; Kimpel J; Tripp CH; Stoitzner P; Bánki Z; von Laer D
Int J Cancer; 2019 Oct; 145(7):1958-1969. PubMed ID: 30972741
[TBL] [Abstract][Full Text] [Related]
40. Viro-immune therapy: A new strategy for treatment of pancreatic cancer.
Ibrahim AM; Wang YH
World J Gastroenterol; 2016 Jan; 22(2):748-63. PubMed ID: 26811622
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
